文献速递神经康复

预后靶向设计可提升上肢卒中康复随机对照试验的统计效能与效率

Prognostic Targeting Improves Statistical Power and Efficiency in Randomized Controlled Trials in Upper Extremity Stroke Rehabilitation.
PubMed 文献 · Neurorehabil Neural Repair · 2025-09-22

该研究基于4项前瞻性队列研究(N=372)的汇总数据,模拟6个月ARAT结局,评估预后靶向对早期卒中上肢康复RCT样本量和效率的影响。结果显示,卒中后3周内预后靶向可使所需样本量最多减少56%,试验效率提高40%至45%,在纵向分析中获益持续存在。

要点

  • 卒中后3周内预后靶向可显著降低早期上肢康复RCT所需样本量。
  • 检测6个月ARAT 6分差异时,靶向试验样本量需求较非靶向减少约一半。
  • 纵向分析中预后靶向的效能与效率获益持续存在。

核心结论

  • 预后靶向可改善以ARAT为结局的早期卒中上肢康复试验的统计效能与效率。
  • 强烈推荐在未来卒中康复与恢复研究中采用预后靶向设计。

研究设计与样本

  • 汇总4项前瞻性队列研究共372例卒中患者的纵向数据,评估时间覆盖卒中后1周至6个月。
  • 基于预测6个月结局的既有预后模型生成合成6个月ARAT结局,并进行横断面与纵向分析。
  • 计算不同样本量下达到70%至90%效能所需的样本量,并以估计样本量和纳入率评估试验效率。

主要发现

  • 卒中后3周内预后靶向理论上可使检测6个月ARAT 6分差异所需样本量最多减少56%。
  • 预后靶向使试验效率提高40%至45%。
  • 达到70%至90%效能时,靶向试验分别需要220、270、360例,而非靶向试验分别需要470、560、820例。
  • 纵向分析中预后靶向的获益持续存在。

关键数值与推荐

  • 以ARAT为结局,检测6个月时6分差异,目标效能70%至90%。

临床怎么用

  • 在早期卒中上肢康复RCT设计中,可考虑基于预后模型进行靶向纳入以提高统计效能。
  • 预后靶向有助于在维持足够效能的前提下减少所需样本量,提升试验效率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Randomized Controlled Trials (RCTs) are essential to underpin the superiority of novel interventions affecting upper extremity capacity post-stroke. However, many RCTs are underpowered, due to heterogeneity in recovery. Prognostic targeting may help reduce sample sizes while maintaining sufficient power. OBJECTIVE: This study investigates the effects of prognostic targeting on the required sample size to achieve 70% to 90% power in early post-stroke RCTs with upper extremity capacity measured with the Action Research Arm Test (ARAT) as the outcome. PATIENTS AND METHODS: Serial data from 4 prospective cohort studies (N = 372 stroke patients) were pooled, with assessments from week 1 to 6 months post-stroke. Using this dataset, we generated synthetic 6-month ARAT outcomes and analyzed data cross-sectionally and longitudinally, with and without prognostic targeting based on a pre-existing prognostic model predicting 6-month outcome. We then calculated power for different sample sizes and assessed trial efficiency, determined by the estimated sample size and inclusion rate. RESULTS: Prognostic targeting within 3 weeks post-stroke theoretically reduced the required sample size by up to 56% and improved trial efficiency by 40 to 45% for detecting a 6-point ARAT difference at 6 months. The targeted trials needed 220, 270, and 360 patients vs. 470, 560, and 820 in non-targeted trials for 70% to 90% power. Benefits persisted in longitudinal analyses. CONCLUSION: This study demonstrates the benefits of prognostic targeting for improving power and efficiency in early post-stroke upper extremity trials using ARAT as outcome. We strongly recommend its use in future stroke rehabilitation and recovery studies.

来源:Neurorehabil Neural Repair,查看原文。版权归原作者所有。

引用

  1. Langerak AJ, van der Gun GJ, Meskers CGM, et al. Prognostic Targeting Improves Statistical Power and Efficiency in Randomized Controlled Trials in Upper Extremity Stroke Rehabilitation. Neurorehabil Neural Repair. 2025. PMID: 40980902. doi:10.1177/15459683251369467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。